Study: NCT01871766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgery will be performed for the primary site tumor with the goal of removing tumor cells while maintaining function in the organ or adjacent organs involved.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgery will be performed for the primary site tumor with the goal of removing tumor cells while maintaining function in the organ or adjacent organs involved.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy will be delivered at approximately week 13 (intermediate risk) or week 19 (high risk) after initiation of chemotherapy. Certain patients will receive radiation at week 4.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy will be delivered at approximately week 13 (intermediate risk) or week 19 (high risk) after initiation of chemotherapy. Certain patients will receive radiation at week 4.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy will be delivered at approximately week 13 (intermediate risk) or week 19 (high risk) after initiation of chemotherapy. Certain patients will receive radiation at week 4.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy will be delivered at approximately week 13 (intermediate risk) or week 19 (high risk) after initiation of chemotherapy. Certain patients will receive radiation at week 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Dosage and route of administration: 15 mg/kg/dose/day IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Dosage and route of administration: 15 mg/kg/dose/day IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Dosage and route of administration: 90 mg/m\^2/dose twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Dosage and route of administration: 90 mg/m\^2/dose twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myeloid Growth Factor
Description: If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice.~High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myeloid Growth Factor
Description: If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice.~High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myeloid Growth Factor
Description: If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice.~High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myeloid Growth Factor
Description: If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice.~High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Sampling
Description: Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in at risk patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Sampling
Description: Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in at risk patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Sampling
Description: Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in at risk patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Sampling
Description: Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in at risk patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Dosage and Route Administration: During interval compressed therapy - irinotecan 50mg/m\^2 IV (maximum dose 100 mg/day) daily x 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Dosage and Route of Administration: During interval compressed therapy - Age \> 1 year: 1800 mg/m\^2/day IV x 5 Age \<1 year: treat with 50% doses calculated on a m\^2 basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Dosage and Route of Administration:~Age \>1 year 100 mg/m\^2/day IV x 5 Age \< 1 year treat with 50% doses calculated on a m\^2 basis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Dosage and Route of Administration: Used in substitution for etoposide in participants who experience allergic reaction. It will be administered 100 mg/m\^2/day IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Dosage and route of Administration:~Age ≥1 year, 37.5 mg/m\^2 IV over 1 hour x 2 days Age \<1 year, 18.75 mg/m\^2 (i.e., a 50% dose reduction) IV over 1 hour x 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: Dosage and Route of Administration: Dexrazoxane dose should be 10x that of doxorubicin.~Age ≥1 year, 375 mg/m\^2 IV over 15-30 minutes Age \<1 year, 187l.5 mg/m\^2 (i.e., a 50% dose reduction) IV over 15-30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ^1^1C-methionine
Description: Participants receive \^1\^1C-methionine to relate the distribution, intensity and change in \^1\^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ^1^1C-methionine
Description: Participants receive \^1\^1C-methionine to relate the distribution, intensity and change in \^1\^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ^1^1C-methionine
Description: Participants receive \^1\^1C-methionine to relate the distribution, intensity and change in \^1\^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ^1^1C-methionine
Description: Participants receive \^1\^1C-methionine to relate the distribution, intensity and change in \^1\^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.